Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10827	Companies
234890	Keywords
163749	Articles
125724	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 05/06/2026 at 15:00, 3 months 6 days ago

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Jaguar Health, Inc. discusses developing oral crofelemer for pediatric patients with Intestinal Failure (IF) due to MVID, aiming for Breakthrough Therapy Designation. Initial results show reductions in PS needs

Jaguar Health Pediatric Patients MVID Intestinal Failure Oral Crofelemer
BRIEF

published on 05/04/2026 at 14:35, 3 months 8 days ago

Jaguar Health Launches Neonorm Dog for Pet Digestive Health

Companion Animals Jaguar Health Gut Health Plant-based Neonorm Dog
BRIEF

published on 05/04/2026 at 14:35, 3 months 8 days ago

Jaguar Health lance Neonorm Dog pour la santé digestive des animaux de compagnie

Jaguar Health Santé Intestinale À Base De Plantes Animaux De Compagnie Chien Néonormal
PRESS RELEASE

published on 05/04/2026 at 14:30, 3 months 8 days ago

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Jaguar Health, Inc. announces the launch of Neonorm Dog, a plant-based product for dogs to support stool formation and gut health. Expansion targets companion animal market

Companion Animals Jaguar Health Gut Health Neonorm Dog Plant-based Product
BRIEF

published on 04/29/2026 at 14:35, 3 months 13 days ago

Jaguar Health annonce des résultats d'essais cliniques positifs pour Canalevia-CA1

Crofelemer Jaguar Health Canalevia-CA1 Approbation De La FDA Diarrhée Induite Par La Chimiothérapie
BRIEF

published on 04/29/2026 at 14:35, 3 months 13 days ago

Jaguar Health Reports Positive Trial Results for Canalevia-CA1

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea
PRESS RELEASE

published on 04/29/2026 at 14:30, 3 months 13 days ago

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. advances towards full FDA approval of Crofelemer for treating chemotherapy-induced diarrhea in dogs, supported by positive trial results

Crofelemer FDA Approval Chemotherapy-induced Diarrhea Jaguar Health Inc. Dog Treatment
BRIEF

published on 04/27/2026 at 15:05, 3 months 15 days ago

Jaguar Health obtient une prolongation et annonce un regroupement d'actions

Jaguar Health Approbation Des Actionnaires Regroupement D'actions Inversé Stratégie De Conformité Extension Nasdaq
BRIEF

published on 04/27/2026 at 15:05, 3 months 15 days ago

Jaguar Health Granted Extension and Announces Reverse Stock Split

Reverse Stock Split Jaguar Health NASDAQ Extension Stockholder Approval Compliance Strategy
PRESS RELEASE

published on 04/27/2026 at 15:00, 3 months 15 days ago

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Jaguar Health announces approval for reverse split at April 2026 Special Meeting of Stockholders. Stock split to begin trading on split-adjusted basis on April 30, 2026. Nasdaq grants extension for compliance with $1.00 bid price rule

Special Meeting Jaguar Health Nasdaq Compliance Reverse Split Stockholders

Accesswire

Published on 08/12/2026 at 15:42, 5 hours 38 minutes ago

Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
Published on 08/12/2026 at 15:42, 5 hours 38 minutes ago

Critical Elements redémarre son programme de forage estival de 10 000 mètres à Rose Ouest avec des résultats positifs
Published on 08/12/2026 at 15:00, 6 hours 20 minutes ago

Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 6 hours 35 minutes ago

Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/12/2026 at 14:30, 6 hours 50 minutes ago

Recent Corporate Events Recap

View all ACCESSWIRE

EQS Group

Published on 08/12/2026 at 21:05, 15 minutes ago

Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
Published on 08/12/2026 at 19:57, 1 hour 23 minutes ago

EQS-Adhoc: Hypoport SE: Hypoport SE resolves share buyback programme with a volume of up to EUR 10 million
Published on 08/12/2026 at 19:37, 1 hour 42 minutes ago

EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Published on 08/12/2026 at 18:50, 2 hours 30 minutes ago

Holding(s) in Company
Published on 08/12/2026 at 18:29, 2 hours 51 minutes ago

Designated Persons Notifications

Les Echos

Published on 08/11/2026 at 17:45, 1 day 3 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 3 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 3 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 3 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 2 days 3 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE